Parts A & C: patients must have either measurable or evaluable disease Parts B, D & E: patients must have measurable disease for Parts B-B, D-D, E and E; melanoma patients in Part B must have either measurable or evaluable disease; neuroblastoma patients in Parts B and D must be evaluable for MIBG response without evidence of RECIST measurable lesions Measurable or evaluable disease Patients must have either measurable or evaluable disease Patients must have either measurable or evaluable disease Disease status:\r\n* Part A: Patients must have either measurable or evaluable disease\r\n* Parts B and C: Patients must have measurable disease on imaging Part A: Patients must have either measurable or evaluable disease Patients must have either measurable or evaluable disease Radiologically measurable or clinically evaluable disease Patients must have either measurable or evaluable disease Patient must have measurable or evaluable disease Radiologically measurable and clinically evaluable disease Metastatic breast cancer (measurable or evaluable including bone metastases only) Measurable or evaluable disease. Evaluable disease Patients must have measurable or evaluable disease Participants enrolling to the phase I portion of the trial must have evaluable or measurable disease Measurable or evaluable disease Evaluable disease; either measurable on imaging or with informative tumor marker. Participants must have evaluable or measurable disease Participants enrolling to the phase I portion of the trial must have evaluable or measurable disease Patients must have measurable or evaluable disease Part A: Patients must have either measurable or evaluable disease Patients must have either measurable or evaluable disease Patients must have measurable or evaluable disease Measurable or evaluable disease. Patients must have measurable or evaluable disease Patients must have measurable or evaluable disease Patients must have evaluable or measurable disease Evaluable disease by RANO. Patients must have either measurable or evaluable disease Patients must have evaluable OR measurable disease Presence of radiographically evaluable disease Measurable disease as defined by irRECIST. Patients with castrate-resistant prostate cancer can have measurable or evaluable disease. Patients with evaluable disease must have documented evidence of progressive disease as defined by any of the following: Patients must have evaluable disease on imaging Have evaluable disease Measurable and/or evaluable disease per Lugano classification Have evaluable disease Evidence of evaluable disease Evidence of measurable or evaluable disease Participants must have evaluable or measurable disease in accordance with the International Working Group Guidelines for Lymphoma. Evaluable disease PHASE I: Patients must have evaluable disease Measurable or evaluable disease Evaluable or measurable disease that meets the following criteria: Patients must have either measurable or evaluable disease Patients must have either measurable or evaluable disease. Patient must have either measurable or evaluable tumor Arms , , : patients should have clinically measurable or evaluable malignant disease Patients must have measurable or evaluable disease Radiologically measurable or clinically evaluable disease Patients must have measurable or evaluable disease Patient must have evaluable disease Evidence of measurable or evaluable disease by clinical, radiographic, or laboratory assessment Patient must have evaluable disease; measurable disease is not required Patients with DSCRT are not required to have measurable or evaluable disease Measurable or evaluable disease: measurable disease in dimensions on imaging studies performed within weeks of starting treatment Has evaluable or measurable disease for response assessment Presence of measurable or evaluable disease. Patients without measurable or evaluable disease. For Part , evaluable or measurable disease PRE-REGISTRATION: Documentation of measurable or evaluable non-measurable disease. Presence of evaluable disease according to the Lugano classification. Patients with evaluable disease will be eligible Patients must have measurable or evaluable disease Patients must have either measurable or evaluable disease Patients must have either measurable or evaluable disease Patients must have evaluable disease Patients must have either measurable or evaluable disease Patients may have measurable or evaluable disease Disease status:\r\n* Phase (Part A): Patients must have either measurable and/or evaluable disease\r\n* Phase (Part B): Patients with neuroblastoma must have proven ALK+ disease with either measurable and/or evaluable disease as indicated below:\r\n** Measurable tumor on magnetic resonance imaging (MRI), computed tomography (CT) scan or X-ray obtained within weeks prior to study enrollment\r\n** Evaluable tumor by meta-iodobenzyl guanidine I (MIBG) scan and/or bone marrow involvement with tumor cells seen on routine morphology \r\n* Phase (Part C): Patients must have proven ALK+ disease with either measurable or evaluable disease Patients must have measurable or evaluable disease Evaluable disease; All patients must have at least ONE site of evaluable disease. Measurable disease or evaluable disease with relevant tumor marker elevation. Measurable or evaluable disease Must have evaluable or measurable disease Evaluable disease Measurable or evaluable disease. Patients must have evaluable disease on MRI imaging Patients are required to have evaluable disease Patients must have either measurable or evaluable disease Presence of measurable or evaluable disease PHASE I: Either measurable or evaluable disease is allowed Patients must have measurable or evaluable disease Patients with measurable or evaluable disease are eligible Evaluable or measurable disease Patients must have evaluable disease for response Patients with recurrence who undergo resection and are left without measurable or evaluable disease are eligible Patients must have measurable or evaluable disease Measurable or evaluable disease Patients must have measurable or evaluable disease Evaluable/measurable disease Non-CLL B-cell malignancies (Arms A, C, and D): Radiographically measurable or evaluable disease Measurable or evaluable disease The participant has a radiographically measurable tumor. Evaluable disease is acceptable for Part only Histologically confirmed, measurable or evaluable disease; patients should have at least one measurable lesion Radiographically measurable or evaluable disease Radiographically measurable or evaluable disease Radiographically measurable or evaluable disease. Measurable or evaluable disease based on IWCLL criteria Patients must have evaluable or measurable malignant disease at enrollment Evaluable disease Metastatic cancer with evaluable disease Presence of measurable or evaluable disease Measurable disease with elevated PSA or evaluable disease (PSA elevation will constitute evaluable disease) Evaluable disease or disease measurable Patients must have either measurable or evaluable disease Have measurable or evaluable disease. Patients may have measurable or non-measurable but evaluable disease. Disease status must be that of measurable and/or evaluable disease Measurable or evaluable disease (as defined in the study protocol) Measurable or evaluable disease by gadolinium MRI or contrast CT scan; note: patients who have had a gross total resection (GTR) are eligible on the basis of evaluable disease Measurable or evaluable disease Measurable or evaluable disease Patients must have evaluable or measurable tumor(s) Evaluable or measurable disease PHASE I: Patients may have measurable or evaluable disease only Evaluable or measurable disease At least one measurable lesion or evaluable disease Patients must have evaluable disease Patients must have measurable or evaluable disease Evidence of measurable or evaluable disease For Parts A and B, participants must have evaluable or measurable disease Presence of evaluable disease Must have measurable or evaluable disease Participants must have measurable or evaluable disease All patients must have measurable or evaluable disease Measurable or evaluable disease